AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02407366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (125 mg ,Three times daily)
Study NCT02407366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed(500mg/m2)every 21 days
Study NCT02407366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC，5) every 21 days
Study NCT02407366 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic radiotherapy(TRT)
Description: TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
Study NCT02407366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy(TRT)
Description: TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
Study NCT02273726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered per dose and schedule specified in the arm.
Study NCT02273726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm.
Study NCT01998126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
Study NCT01998126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
Study NCT01998126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
Study NCT01998126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT04063254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Study NCT04063254 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Study NCT00781820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifonazole cream 1%
Description: 1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
Study NCT00781820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
Study NCT03040310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back Rx program
Description: The Back Rx program can be viewed via a smartphone app.
Study NCT03203551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Study NCT03203551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfection Protocol
Description: The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Study NCT04311567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Study NCT04311567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Study NCT00866697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg tablet daily for 104 weeks (24 months)
Study NCT00866697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Study NCT00496795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: epirubicin/docetaxel sequential
Description: Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
Study NCT04312464 — intervention group
Intervention type: OTHER
Intervention: non
Description: no intervention
Study NCT03228758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per Oral Endoscopic Myotomy
Description: The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
Study NCT03457883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: herniamesh
Description: Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
Study NCT03457883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biological graft
Description: Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
Study NCT02435589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic pain assessment
Description: Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
Study NCT02435589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic pain assessment
Description: Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
Study NCT02435589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification of results of assessments
Description: Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
Study NCT01974596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic tablets of Lactobacillus reuteri
Study NCT01857492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Study NCT01857492 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study NCT01857492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation
Description: Both Active and SHAM groups will receive Meditation.
Study NCT01857492 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Meditation
Description: Both Active and SHAM groups will receive Meditation.
Study NCT01974596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Study NCT02978079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated pupillometry
Description: Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
Study NCT01428661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg once daily
Study NCT01428661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily
Study NCT05425706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of SNAGs technique
Description: in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
Study NCT02887027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise4Mood Intervention
Description: The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
Study NCT03002519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-R18
Description: Intramuscular (IM) administration of PLX-R18
Study NCT03944135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web platform: Neuronup
Description: Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
Study NCT03944135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web platform: Neuronup
Description: Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
Study NCT01563185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen/26.6 mg famotidine
Description: Oral tablet taken three time per day
Study NCT02049034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days.
Study NCT02049034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lixisenatide
Description: Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days.
Study NCT02049034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
Study NCT03075072 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation
Description: Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
Study NCT03075072 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation (SRS)
Description: Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
Study NCT06365424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate (200 mg/day)
Study NCT06365424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: Ursodeoxycholic acid (13-15 mg/kg/day)
Study NCT06365424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: Ursodeoxycholic acid (13-15 mg/kg/day)
Study NCT04103619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuTite
Description: Subjects will undergo treatment with AccuTite
Study NCT04103619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuTite + Morpheus 8
Description: Subjects will undergo treatment with AccuTite and Morpheus 8
Study NCT01749215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Experimental study drug
Study NCT01749215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator
Study NCT01749215 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Brief alcohol counseling
Study NCT01749215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Brief alcohol counseling
Study NCT02874872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OASIS Collaborative
Description: OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
Study NCT01162096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haploidentical Allogeneic Transplantation
Description: Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
Study NCT02049034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
Study NCT00926549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
Description: macular cube scanning
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg Oral Capsule
Description: aprepitant 80 mg orally one hour prior to scheduled surgery
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine transdermal
Description: scopolamine transdermal patch one hour prior to scheduled surgery
Study NCT03435003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Maintenance of anesthesia without the use of inhaled anesthetics.
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg intraoperatively
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg intraoperatively
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reglan
Description: Postoperatively scheduled Reglan
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reglan
Description: Postoperatively scheduled Reglan
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Postoperatively scheduled ondansetron
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Postoperatively scheduled ondansetron
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine
Description: Postoperatively as needed compazine for breakthrough PONV
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compazine
Description: Postoperatively as needed compazine for breakthrough PONV
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal with sugammadex
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Reversal with sugammadex
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous anesthesia will be maintained through IV propofol
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: maintenance of anesthesia in the intervention arm
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalational anesthesia
Study NCT03435003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: inhalational anesthesia
Study NCT04631627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
Study NCT04631627 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
Study NCT01409616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral
Study NCT01409616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban (double dose)
Description: oral
Study NCT01409616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: oral
Study NCT01409616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: oral
Study NCT00222053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Per os thalidomide
Study NCT00222053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphosphonates
Description: Biphosphonates
Study NCT01544699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS (ELDITH)
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
Study NCT01544699 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (ELDITH)
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
Study NCT03695315 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP is a noninvasive treatment for sleep apnea
Study NCT02665065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iomab-B
Study NCT02665065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Study NCT02665065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Study NCT02665065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HCT
Study NCT01944735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
Study NCT01944735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15